The session below was sponsored by Takeda during the ESPID 2025 Meeting and is intended for HCPs only. *Not included in the main event CME/CPD credit.

Session Description:

The session addresses the critical issue of dengue, starting with an overview of Qdenga. The program provides a comprehensive understanding of the dengue’s impact by examining the pediatric burden of dengue and prevention/management strategies from both non-endemic and endemic perspectives. A key focus is on the real-world experience of Qdenga in dengue prevention, utilizing data from the Vacunar Network in Argentina. The session concludes with an interactive Q&A session.

Francesca F Norman
(Spain)

MBBS, BMedSci, PhD, FISTM Counsellor, ISTM Executive Board, 2021-2025. Specialist training in Internal Medicine, Master´s degree in Tropical Medicine and International Health.

Kleber Luz
Brazil

Associate Professor IV at the Institute of Tropical Diseases at the Federal University of Rio Grande do Norte

Vanesa Edelvais Castellano
(Argentina)

Medical Doctor specialized in Pediatrics from the University of Buenos Aires (UBA)

Note that this recording is intended for HCPs only.

 
const checkbox = document.getElementById('myCheckbox1'); const link = document.getElementById('myLink1'); checkbox.addEventListener('change', function() { if (checkbox.checked) { link.classList.remove('disabled'); } else { link.classList.add('disabled'); } });

This promotional symposium has been commissioned and funded by GSK and is for Healthcare Professionals only.

*Not included in the main event CME/CPD credit.

Session Description:

Link to prescribing information for GSK products mentioned during this symposium can be found here under.  Adverse event reporting information can be found at the bottom of this webpage.
EU: https://www.ema.europa.eu/en/documents/product-information/bexsero-epar-product-information_en.pdf
UK: Bexsero Meningococcal Group B vaccine for injection in pre-filled syringe – Summary of Product Characteristics (SmPC) – (emc) | 5168

Adverse events should be reported. For Great Britain and Northern Ireland, reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline +44 0800 221 441
For other countries please access reporting information at Report a possible side effect | GSK

1677508634086

Teresa Bruce
(USA)

GSK Global Medical Director.

Marco Safadi

Marco Aurelio Palazzi Safadi
Brazil

Associate Professor of Paediatrics. Head of the Division of Paediatric Infectious Diseases – Santa Casa de Sao Paulo School of Medical Sciences.

Foto Irene Rivero

Irene Rivero Calle

(Spain)

Consultant in Paediatrics and Paediatric Infectious Diseases at Hospital Clínico Universitario de Santiago de Compostela.

_Ulrich Heininger UKBB

Ulrich  Heininger

(Switzerland)

Paediatrician specializing in infectious diseases and vaccinology. University of Basel Children’s Hospital (UKBB).

Note that this recording is intended for HCPs only.

 
const checkbox = document.getElementById('myCheckbox2'); const link = document.getElementById('myLink2'); checkbox.addEventListener('change', function() { if (checkbox.checked) { link.classList.remove('disabled'); } else { link.classList.add('disabled'); } });